Jove
Visualize
Contact Us

Related Concept Videos

Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

163
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
163
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

486
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
486
Clinical Trials01:16

Clinical Trials

6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subthreshold intracortical microstimulation of human somatosensory cortex enhances tactile sensitivity.

Brain stimulation·2025
Same author

Artificial touch feedback using microstimulation of human somatosensory cortex to convey grip force from a robotic hand.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Characteristics and stability of sensorimotor activity driven by isolated-muscle group activation in a human with tetraplegia.

Scientific reports·2022
Same author

Perceived timing of cutaneous vibration and intracortical microstimulation of human somatosensory cortex.

Brain stimulation·2022
Same author

Intracortical microstimulation of somatosensory cortex enables object identification through perceived sensations.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2021
Same author

Intracortical Somatosensory Stimulation to Elicit Fingertip Sensations in an Individual With Spinal Cord Injury.

Neurology·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 13, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K

Navigating the FDA regulatory landscape.

Pamela D Scott1, Anita Bajaj2, David P McMullen2

  • 1Food and Drug Administration, Center for Devices and Radiological Health, Office of Product Evaluation and Quality, Office of Neurological and Physical Medicine Devices, 10903 New Hampshire Ave., Silver Spring, MD, 20993, USA. PamelaD.Scott@fda.hhs.gov.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|October 18, 2023
PubMed
Summary
This summary is machine-generated.

Novel medical devices offer rapid treatments for neuropsychiatric disorders. This perspective reviews FDA regulatory pathways for neuromodulation devices, emphasizing early engagement and patient input for developers.

More Related Videos

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.4K
Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator
07:06

Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator

Published on: May 14, 2020

5.1K

Related Experiment Videos

Last Updated: Jul 13, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.6K
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

3.4K
Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator
07:06

Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator

Published on: May 14, 2020

5.1K

Area of Science:

  • Neuroscience and Psychiatry
  • Medical Device Technology
  • Regulatory Science

Background:

  • Advancements in research and technology are driving the development of novel, fast-acting therapeutics for neuropsychiatric disorders.
  • Medical devices, including brain stimulation/recording technologies and digital therapeutics, represent a growing area of innovation.

Purpose of the Study:

  • To provide an overview of the U.S. Food and Drug Administration (FDA) regulatory oversight for medical devices.
  • To discuss regulatory pathways and review processes specific to neuromodulation devices for psychiatric conditions.
  • To highlight strategies for developers interacting with the FDA, including special programs and patient perspective integration.

Main Methods:

  • Review of FDA regulatory frameworks and guidance documents pertaining to medical devices.
  • Analysis of current and emerging neuromodulation technologies for psychiatric disorders.
  • Exploration of regulatory considerations and best practices for device developers.

Main Results:

  • The FDA employs various regulatory pathways for medical devices, with specific considerations for psychiatric neuromodulation technologies.
  • Early and solution-focused engagement with the FDA is crucial for device developers.
  • Special FDA programs can assist developers in navigating the regulatory landscape.

Conclusions:

  • Navigating the regulatory landscape for psychiatric neuromodulation devices requires strategic planning and proactive engagement with the FDA.
  • Incorporating patient perspectives is essential for the successful development and approval of these novel treatments.
  • The future holds promising rapid treatment options for psychiatric disorders, supported by evolving regulatory science.